| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Unknown | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Resid NCT04197687 | Academic and Community Cancer Research United | Phase 2 |
| Terminated | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Patho NCT03872388 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence NCT04054557 | Thomas Jefferson University | N/A |
| Completed | SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer NCT03411070 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Canc NCT03199885 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors NCT03407716 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery NCT03317405 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and N NCT03094052 | University of California, San Francisco | Phase 2 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Insta NCT03428802 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treatin NCT03101748 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positi NCT03281902 | Mayo Clinic | — |
| Completed | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast NCT03106415 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnos NCT02883062 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Tr NCT03012100 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer NCT02954874 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC NCT02593175 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Tr NCT02689427 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment NCT02754752 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer NCT02474173 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer NCT02276443 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estro NCT02311933 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | The Role of Lifestyle Factors in Breast Cancer-Related Outcomes NCT02079662 | M.D. Anderson Cancer Center | N/A |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer NCT01463072 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer NCT00496795 | University of Bergen | Phase 2 |
| Completed | Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer NCT00376688 | National Cancer Institute (NCI) | Phase 2 |